Davide Melisi, MD, PhD, discusses the potential of NALIRIFOX as a new first-line standard of care for patients with metastatic pancreatic ductal adenocarcinoma, noting that pending FDA approval, this effective and tolerable regimen could also inform future clinical trials designs for patients with pancreatic cancer.